首页> 美国卫生研究院文献>Pharmaceutics >Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug Doxorubicin
【2h】

Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug Doxorubicin

机译:抗肿瘤药在卵巢癌球体中的渗透效率:重组靶向毒素DARPin-LoPE和化疗药物阿霉素的情况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors determining the prospects for its clinical use. This problem is particularly acute in the case of targeted antitumor agents since many of them are high-molecular-weight compounds. In this work, the penetration of therapeutic agents of two distinct molecular weights into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied. It was shown that the low-molecular-weight chemotherapy drug, doxorubicin (~0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 μm spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (~42 kDa), is only a few surface layers of cells and does not exceed 70 μm. The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture. The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed.
机译:将治疗剂递送到肿瘤中的效率是决定其临床应用前景的关键因素之一。在靶向抗肿瘤剂的情况下,该问题尤其严重,因为它们中的许多是高分子量化合物。在这项工作中,研究了两种不同分子量的治疗剂对过表达人表皮生长因子受体2(HER2)的卵巢腺癌小球的渗透性。结果表明,低分子量化学疗法药物阿霉素(〜0.5 kDa)可有效穿透300至400μm球状体的几乎整个深度,而HER2特异性重组靶向毒素DARPin- LoPE(〜42 kDa)仅是细胞的一些表面层,不超过70μm。与二维单层培养相比,显示出目标毒素对球体的低渗透性以及其对抗三维肿瘤球体的效率显着降低。介绍了增加药物在肿瘤中的蓄积的方法,并讨论了其用于改善治疗效果的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号